Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
84 results about "Brimonidine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Brimonidine is used to relieve redness in the eyes caused by minor eye irritations (such as smog, swimming, dust, or smoke)..
Method and Kit for Treating or Preventing Psoriasis
InactiveUS20110118267A1Treating and preventing psoriasisLittle side effectsBiocideInorganic non-active ingredientsGynecologyAdrenergic
Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine.
Owner:GALDERMA LAB LP
Compositions and methods for reducing activation of alpha-1 receptors
The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Combination of brimonidine and timolol for topical ophthalmic use
Owner:ALLERGAN SALES LLC
Composition and methods for treating allergic response
The invention generally relates to compositions and methods for treating and / or preventing an allergic response with reduced rebound hyperemia, comprising highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume, and histamine antagonists. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Combination of brimonidine and timolol for topical ophthalmic use
Owner:ALLERGAN SALES LLC
Vasoconstriction compositions and methods of use
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Compositions and Methods for Improving Night Vision
InactiveUS20120277239A1Improve night visionReduced and eliminated side effectBiocideSenses disorderNight visionAdrenergic
The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
Owner:EYE THERAPIES
Compositions and methods for treatment of diseases and conditions with increased vascular permeability
InactiveUS20100197694A1Reduce vascular permeabilityReduce transmissionBiocideDispersion deliveryDiseaseAdrenergic
The invention provides compositions and methods for treating diseases and conditions through reducing vascular permeability, selectively inhibiting VEGF-induced postcapillary venular leakage, and / or selectively reducing spread of viral and / or bacterial pathogens. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and / or dexmedetomidine.
Owner:EYE THERAPIES
Sustained drug delivery implant
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
Owner:ALLERGAN INC
Intraocular drug delivery systems
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants such as microsheres provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer. The active is selected from estradiols such as 2-methoxyestradiol or alpha2-adrenergic agonists such as brimonidine and its derivates or prostagladin analogis.
Owner:ALLERGAN INC
Methods of preventing and reducing the severity of stress-associated conditions
InactiveUS20080207627A1Prevention and reduction of severityBiocideNervous disorderMuscle contractionWhole body
The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
Owner:GIL DANIEL W +3
Methods of preventing and reducing the severity of stress-associated conditions
InactiveUS7977335B2Prevention and reduction of severityBiocideNervous disorderMuscle contractionHyperesthesia
Owner:ALLERGAN INC
Preferential vasoconstriction compositions and methods of use
The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Compositions and methods for treatment of pulmonary diseases and conditions
InactiveUS20100202979A1Reduce vascular permeabilityBig gapBiocideDispersion deliveryDiseaseAdrenergic
The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and / or dexmedetomidine.
Owner:ALPHA SYNERGY DEV
Combination treatment for dermatological conditions
InactiveUS20120076738A1Good curative effectEliminate side effectsBiocideAntimycoticsCombined treatmentOxymetazoline
The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.
Owner:GALDERMA LAB LP
Method for treating psoriasis
InactiveUS8394800B2Treating and preventing psoriasisLittle side effectsBiocideInorganic non-active ingredientsΑ2 adrenergic receptorPharmacology
Owner:GALDERMA LAB LP
Methods of preventing and reducing the severity of stress-associated conditions
InactiveUS20080207628A1Prevention and reduction of severityBiocideNervous disorderMuscle contractionPanic
The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
Owner:ALLERGAN INC
Compositions and methods for ophthalmic delivery of nasal decongestants
InactiveUS20110152271A1Relieve nasal congestionReduce nasal decongestionBiocideOrganic chemistryNoseAdrenergic receptor agonists
The invention provides compositions and methods for treating nasal congestion through ophthalmic delivery. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
Owner:HORN GERALD
Pharmaceutical Composition for Treatment of Ocular Hypertension
InactiveUS20090048261A1Reducing ocular hypertensionReduce dilution effectBiocideSenses disorderPharmaceutical industryDorzolamide
The present invention is related to the pharmaceutical industry in general and in particular with the pharmaceutical industry of production of ophthalmic compositions. More specifically, the present invention relates to the pharmaceutical industry of production of ophthalmologic compositions for the treating of ocular hypertension. The advantage of the present invention against the present state of the technique is the fulfilling of a synergic effect of its components for the decreasing of ocular hypertension with no antagonistic effect between its components. The present invention consists of a pharmaceutical composition for the treatment of ocular hypertension characterized by comprising a pharmacologically effective amount of dorzolamide, with a pharmacologically effective amount of timolol and a pharmacologically effective amount of brimonidine.
Owner:BAYARDO ARTURO JIMENEZ
Compositions and methods for reducing capillary permeability
The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Owner:EYE THERAPIES
Combination treatment for rosacea
InactiveUS20120082625A1Good curative effectEliminate side effectsBiocideAntipyreticOxymetazolineBrimonidine
The invention relates to a method of treating erythema and / or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and / or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.
Owner:GALDERMA LAB LP
Methods and compositions for safe and effective treatment of erythema
ActiveUS20110286944A1Safe and effective of and symptomSafe and effective treatmentBiocideCosmetic preparationsBrimonidineErythema
Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.
Owner:GALDERMA LAB LP
Fixed dose combination of bimatoprost and brimonidine
InactiveUS20130023536A1Improve their wellbeingRelieve symptomsBiocideSenses disorderBrimonidineTreatment glaucoma
The present invention is directed to compositions comprising combinations of brimonidine and bimatoprost useful for lowering intraocular pressure in a patient and for the treatment of glaucoma
Owner:ALLERGAN INC
Compositions and methods for the treatment of nasal conditions
The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
Owner:PS THERAPIES LTD
Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
InactiveUS20070203144A1Decreasing VEGF levelElevated VEGFBiocideSenses disorderDiseaseBlood-retina barrier
Reducing the VEGF level in a patient suffering from an ocular disease or condition which is characterized by elevated VEGF and / or blood retina barrier (BRB) breakdown which comprises treating said patient with an effective amount of a compound selected from the group consisting of memantine, brimonidine and mixtures thereof.
Owner:ALLERGAN INC
Compositions and methods for treatment of pulmonary diseases and conditions
InactiveUS20110244058A1Promote absorptionImprove permeabilityBiocideOrganic chemistryDiseaseAdrenergic receptor agonists
The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors or ketamine at specific pH. The compositions preferably comprise brimonidine and / or dexmedetomidine and / or ketamine.
Owner:EYE THERAPIES
Combination treatment for dermatological conditions
InactiveUS20140094470A1Good curative effectEliminate side effectsBiocideAntimycoticsCombined treatmentOxymetazoline
Owner:GALDERMA LAB LP
Method for preventing or treating skin tumor
Owner:GALDERMA RES & DEV SNC
Methods and compositions for safe and effective treatment of erythema
Owner:GALDERMA LAB LP
Vasoconstriction compositions and methods of use
PendingUS20180360825A1Reducing eye rednessHigh whitenessOrganic active ingredientsSenses disorderArteriolar VasoconstrictionAdrenergic
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.
Owner:EYE THERAPIES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com